17.3-month median OS in pancreatic cancer, roughly double the standard of care, now in Phase 3 — thesis resolves on whether the randomized trial replicates it

Immuneering is a clinical-stage company developing a targeted cancer drug combined with chemotherapy to treat pancreatic cancer, which is not yet approved.

Atebimetinib, an oral MEK inhibitor added to gemcitabine plus nab-paclitaxel, produced 17.3-month median overall survival in 55 first-line pancreatic cancer patients, roughly double the historical standard-of-care benchmark. The thesis resolves on whether Phase 3 MAPKeeper 301, now enrolling, reproduces that survival benefit against a concurrent control arm. Single-arm Phase 2a data driving a Phase 3 design carries the inherent risk that patient selection or site effects inflated the signal.